Axovant Sciences has renamed itself Axovant Gene Therapies to put a seal on its switch from repurposing small-molecule drugs toward becoming a player at the cutting edge of genetic medicine.
Just a few weeks after Vivek Ramaswamy’s Axovant $AXON got a big boost out of its licensing pact with Oxford BioMedica for what is now called AXO-Lenti-PD, a gene therapy designed to spur dopamine production in the brain, the biotech is continuing its makeover with a new deal adding a fresh set of gene therapies to the pipeline.
Roivant’s Vivek Ramaswamy may have run into a nasty mess with the failure of Axovant’s lead Alzheimer’s drug, but he can still recruit top talent for his growing organization.